New Delhi, Dec. 11 -- Danish drugmaker Novo Nordisk has moved the Delhi High Court's division bench seeking to restrain Dr Reddy's Laboratories from domestically manufacturing and exporting semaglutide - the blockbuster weight-loss and diabetes drug - to non-patent countries until its patent expires in March 2026.

According to the court's cause list, Novo's appeal is listed tomorrow before a division bench of Justice C. Hari Shankar and Justice Om Prakash Shukla.

The appeal challenges the 2 December order of Justice Manmeet Pritam Singh Arora, which allowed Dr. Reddy's to continue manufacturing and exporting semaglutide to non-patent countries until the patent expires, while restraining domestic sales until 2026. Justice Arora had decli...